Compare Deere & Company (DE) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Moderna, Inc. — how do they compare? Deere & Company trades at $626.38 (market cap $175.95B), while Moderna, Inc. trades at $220.73 (market cap $78.65B). The key difference: Deere & Company is far larger — about 2.2× Moderna, Inc.'s market cap, and Deere & Company pays a 0.99% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and Moderna, Inc. for 59 Days on average.
| DE | MRNA | |
|---|---|---|
Market Cap | $175.95B | $78.65B |
Volume | 1,387,231 | 37,373,437 |
Sector | Industrials | Health |
52-Week High | $709.48 | $203.46 |
52-Week Low | $439.11 | $22.36 |
Typical Hold Time | 75 Days | 59 Days |
Enterprise Value | $229.85B | $74.80B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $627.66, down 4.45% on the day, reflecting near-term pressure amid a bearish technical signal. The stock has demonstrated consistent earnings beats in recent quarters, with Q2 2026 EPS of $5.10 surpassing the $4.69 estimate. However, revenue has declined from $60.2B in 2023 to $44.7B in 2025, compressing net margins. Analyst consensus remains optimistic with a $731.20 price target, supported by a 43.48% buy rating.
The outlook balances strong profitability metrics like an 18.4% ROE against cyclical headwinds in the agriculture equipment sector. Key risks include further revenue contraction and high debt levels, but institutional accumulation and a strategic focus on AI-driven farming solutions present long-term growth catalysts. The current valuation at a P/E of 36.27 demands sustained earnings expansion to justify upside.
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
